Alzheimer’s Drug Shows Language Improvement for Fragile X Syndrome
A new study published in the Nature Medicine journal has shown that Tetra Therapeutics' Alzheimer's investigational disease drug improves language and learning ability in adults diagnosed with Fragile X Syndrome. Fragile X Syndrome is a genetic condition that causes...
Moderna Working on Improving COVID-19 Vaccine
Moderna, currently one of three companies granted emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) for its COVID-19 vaccine, is continuing its efforts in improving the vaccine. Currently, the vaccine must be stored in cold temperatures;...
Parkinson’s Clinical Trial Approved by FDA
The U.S. Food and Drug Administration (FDA) announced its approval of Hope Biosciences Stem Cell Research Foundation's (HBSCRF) Phase II double blind placebo controlled Parkinson's clinical trial. The clinical trial will test the efficacy and safety of multiple...
Health Canada Grants Marketing Approval to Rockwell Medical for Triferic® AVNU™
Health Canada granted marketing approval today (April 27) to Rockwell Medical for its Triferic AVNU, a ferric pyrophosphate citrate injection designed to replace iron for hemoglobin maintenance in adults with hemodialysis-dependent chronic kidney disease. The drug is...
FDA & CDC Lift Restrictions on J&J Vaccination
The U.S. Food and Drug Administration (FDA) and the Center for Disease Control (CDC) lifted restrictions on the single-shot Johnson & Johnson vaccination for COVID-19 this past Friday (April 23) after the FDA's Advisory Committee on Immunization Practices (ACIP)...
TGA Approves Global Sarcoma Therapy
The Therapeutic Goods Administration (TGA) has approved the use of Global Sarcoma Therapy called YONDELISÒ, marketed by Specialised Therapeutics, for Australian patients afflicted with "unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior...
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com